NOCIL Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Volume growth, margin squeeze: Q4 revenue rose 7% QoQ to ₹340 crores on 4% volume growth, but FY25 PAT fell to ₹103 crores from ₹133 crores as legacy high-cost inventory and a specialty mix dip compressed spreads.
• Antidumping petition is the central catalyst: The company has filed for duties against China, Korea and the EU, covering products that account for roughly 40% of overall business; the investigation has been initiated with prima facie merit found.
• Pricing pressure is structural, not cyclical: Aggressive dumping by Chinese, Korean and EU manufacturers continues to set the pricing benchmark, and management sees only minimal gross spread improvement ahead absent trade relief.
• Capacity expansion proceeds despite weak utilization: A ₹250 cr Dahej capex for TDQ antioxidants is on track even though overall utilization sits at 65–70% and management cannot forecast when full utilization will be achieved.
• What to watch next quarter: Whether the antidumping investigation yields provisional findings, any shift in import volumes, and whether the specialty chemicals product mix recovers from its Q4 dip.

Antidumping Petition & Trade Environment

• Petition filed, investigation live: The authority has initiated a case after finding prima facie merit and substance in the dumping practices alleged against rubber chemical manufacturers from China, Korea and the EU.
• Scope of relief sought: The petition covers products accounting for around 40% of NOCIL's overall business, making the outcome material to both revenue protection and margin recovery.
• Changed regulatory climate: Management observes that the climate for antidumping cases has shifted, with almost all cases now getting approved based on recent statistics.
• EU pricing follows the benchmark: A leading supplier sets the pricing benchmark, and the EU has followed that same benchmark, leaving NOCIL with no other option on pricing.
• Import volumes steady: Import volumes of accelerators and antioxidants are at similar levels to the previous quarter; in some cases they decreased, but mostly remained at previous levels.
• U.S. tariff uncertainty: The situation presents an opportunity as NOCIL has approvals and customers who can shift purchase share, but lack of clarity on duties means buyers are waiting.

Srinivasan: "What we have seen is the climate has slightly changed this time when we are going for it. Almost most cases are getting approved. That is what we understand today when we see the statistics."

Margins & Cost Structure

• Legacy inventory hit gross spreads: Raw material costs for aniline and nitrobenzene fell sharply in Q4, but the benefit did not flow through because the company was sitting on higher-cost inventory, and demand did not pick up as envisaged.
• Specialty mix dip compounded the pressure: The specialty chemicals segment, normally around 15% of the portfolio, saw a slight correction this quarter, which changed the overall equation and caused the gross margin spread to come down.
• Minimal improvement ahead: Management indicated that given current circumstances, there could be only minimal improvement in gross spreads going forward, with help from legacy cost absorption and operational efficiency measures.
• Per-kg opex optimization is perpetual: The company is making a conscious effort to improve per-kg efficiency parameters quarter-over-quarter, but these are ongoing initiatives with no discrete step-change promised.
• Long-term structural improvement claimed: Management pointed out that operating EBITDA has moved from around 4% in FY12-13 to around 10–10.5% now, arguing this reflects genuine technological improvement over the cycle.

Srinivasan: "Unfortunately, the demand didn't pick up the way we envisaged, and therefore, there is a legacy cost kicked in, in this quarter."

Demand & Volume Growth

• Q4 sequential recovery, FY25 annual decline: Revenue grew 7% sequentially to ₹340 crores with 4% volume growth in both domestic and export markets, but full-year revenue declined to ₹1,393 crores from ₹1,445 crores in FY24.
• Domestic business held back by imports: Domestic growth was flattish, constrained by low-priced imports that continue to pressure volumes despite NOCIL's dominant market share position.
• Export markets are the growth lever: Management expects stronger growth to come from export markets, with the company in different stages of engagement across the U.S., Japan, Malaysia and Thailand, and traction expected this year.
• Volume growth lagged the market: Over the last 3 years, global rubber consumption grew 5.3% while NOCIL volumes grew only 2.2%; management argues the 6-year view is more representative, with NOCIL growing 34% versus the market's 28%.
• Latex segment improved: After a couple of years of underperformance, the Latex business improved in FY25; management sees it continuing to develop but not returning to COVID-era levels.
• Domestic growth outlook tied to tire industry: The Indian tire industry is projected to grow at a 4–6% CAGR over the medium to long term, driven by replacement demand, automotive sector strength, infrastructure spending and favorable policies.

Anand: "We recognize that our recent performance has not met our own aspirations. However, with all the initiatives, both internal and external that are underway, we are confident to build on our growth path."

Capacity & Capex

• Dahej expansion on track: The previously announced ₹250 crores capex at the Dahej facility is progressing as planned, aimed at enhancing production capabilities for the TDQ antioxidant product portfolio using a more advanced process.
• Overall utilization is 65–70%: Current capacity utilization sits at 65–70%, but for specific products the company is fully utilized, which is what the expansion addresses.
• Prior capacity addition still not absorbed: Management acknowledged that capacity added 3–4 years ago has not been fully utilized as expected due to the uncertain environment, and they were unable to clearly forecast when utilization would be achieved.
• Filling existing capacity is the priority: The objective is to fill up volumes for existing capacities, and management sees this happening going forward, though no timeline was given.

Anand: "Given the uncertain environment and all the environment that's changed in the last few quarters, we were not able to really clearly put a finger on when we can really even forecast this utilization of the capacity."

Product Portfolio & R&D

• Specialty chemicals mix dipped in Q4: The specialty segment, normally around 15% of the portfolio, saw a slight correction this quarter; management expects corrections in the coming years but gave no specific timeline.
• New products ambition is internal, not disclosed: Management's internal goal is to significantly increase the specialties contribution from the current ~15%, but they declined to put a specific target or timeline on it.
• R&D progress is a bright spot: The company is quite positive about progress being made in R&D regarding new products, and the new Dahej plant will leverage this technology expertise for a more advanced TDQ process.
• Product basket description narrowed: The portfolio is now described as "20-plus" products rather than the previous "23-plus," with management saying they are not being specific about the exact number.

Anand: "Our goals internally is to significantly increase this number. I don't want to put any specific target, but I think there is a scope for significant improvement on that front."

Guidance & Commitments

Key Metrics